@article{823ba3fb6c734c15b4e4359311cb9b79,
title = "2-Deoxy-D-Glucose and its analogs: From diagnostic to therapeutic agents",
abstract = "The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress cancer cell growth and survival. Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death. In addition to glycolysis inhibition, other molecular processes are also affected by 2-DG. Attempts to improve 2-DG{\textquoteright}s drug-like properties, its role as a potential adjuvant for other chemotherapeutics, and novel 2-DG analogs as promising new anticancer agents are discussed in this review.",
keywords = "2-DG analogs, 2-deoxy-d-glucose, Anticancer therapy, Glioblastoma",
author = "B. Pajak and E. Siwiak and M. So{\l}tyka and A. Priebe and R. Zieli{\'n}ski and I. Fokt and M. Ziemniak and A. Ja{\'s}kiewicz and R. Borowski and T. Domoradzki and W. Priebe",
note = "Funding Information: This work was supported by National Science Centre in Poland (grants No. UMO-2017/25/B/NZ3/00251 and UMO-2017/24/C/NZ1/00366). Grant No. UMO-2017/25/NZ3/00251 is carried out with cooperation of Professor Waldemar Priebe, MD Anderson Cancer Center, where new 2-DG derivatives were synthesized. WP1122 was also designed and produced at MD Anderson Cancer Center with the support from Moleculin Biotech, Inc., and was kindly supplied for research by the Dermin company, which based on the exclusive license, conducts developmental studies of the molecule (Grant. No. UDA-POIG.01.04.00-10-015/11-00). Funding Information: produced at MD Anderson Cancer Center with the support from Moleculin Biotech, Inc., and was kindly Funding Information: Conflicts of Interest: Prof. Priebe is listed as an inventor on patents covering new analogs of 2-DG. He is also a declare no conflict of interest. share holder of Moleculin Biotech Inc., and his research is in part supported by the sponsor research grant from Publisher Copyright: {\textcopyright} 2019 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2020",
month = jan,
day = "1",
doi = "10.3390/ijms21010234",
language = "English (US)",
volume = "21",
journal = "International journal of molecular sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",
}